Erratum: Venlafaxine extended release in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study (Pain (2004) 110 (697-706) PII: S0304-3959(03)00017-4 and 10.1016/j.pain.2004.05.010);Venlafaxine extended release in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study

Pain

Volumn 110, Issue 3, 2004, Pages 697-706

  Rowbotham, Michael C ^a   Goli, Veeraindar ^b   Kunz, Nadia R ^c   Lei, Dean ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

Analgesia; Antidepressants; Diabetic neuropathy; Pain; Venlafaxine extended release (ER)

Indexed keywords

GABAPENTIN; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ANALGESIA; ANOREXIA; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DYSPEPSIA; ELECTROCARDIOGRAPHY MONITORING; FEMALE; FLATULENCE; HUMAN; IMPOTENCE; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINUSITIS; SOMNOLENCE; SWEATING; VISUAL ANALOG SCALE; VOMITING;

EID: 3843053823     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2004.11.021     Document Type: Erratum

References (50)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV™ 4th ed:1994;American Psychiatric Association, Washington, DC
2. Ananth J., Burgoyne K., Smith M., Swartz R. Venlafaxine for treatment of obsessive-compulsive disorder. Am J Psychiatry. 152:1995;1832
3. Arias F., Padín J.J., Gilaberte I., et al. Comparative efficacy and tolerability among different selective serotonin re-uptake inhibitors and venlafaxine in a naturalistic setting. Int J Psychiatry Clin Prac. 2:1998;255-260
4. Atkinson J.H., Slater M.A., Williams R.A., Zisook S., Patterson T.L., Grant I., Wahlgren D.R., Abramson I., Garfin S.R. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain. 76:1998;287-296
5. Atkinson J.H., Slater M.A., Wahlgren D.R., Williams R.A., Zisook S., Pruitt S.D., Epping-Jordan J.E., Patterson T.L., Grant I., Abramson I., Garfin S.R. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain. 83:1999;137-145
6. Backonja M., Beydoun A., Edwards K.R., Schwartz S.L., Fonseca V., Hes M., LaMoreaux L., Garofalo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. J Am Med Assoc. 280:1998;1831-1836
7. Ball S.E., Ahern D., Scatina J., Kao J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol. 43:1997;619-626
8. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 4:1961;561-571
9. Boulton A.J.M., Knight G., Drury J., Ward J.D. The prevalence of symptomatic, diabetic neuropathy in an insulin-treated population. Diabetes Care. 8:1985;125-128
10. Cook R.J., Sackett D.L. The number needed to treat: a clinically useful measure of treatment effect. Br Med J. 310:1995;452-454
11. Dierick M., Ravizza L., Realini R., Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry. 20:1996;57-71
12. Dwight M.M., Arnold L.M., O'Brien H., Metzger R., Morris-Park E., Keck P.E.J. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics. 39:1998;14-17
13. Farrar J.T., Young J.P., LaMoreaux L., Werth J.L., Poole R.M. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 94:2001;149-158
14. Fields H.L., Heinricher M.M., Mason P. Neurotransmitters in nociceptive modulatory circuits. Ann Rev Neurosci. 14:1991;219-245
15. Goodnick P.J., Jimenez I., Kumar A. Sertraline in diabetic neuropathy: preliminary results. Ann Clin Psychiatry. 9:1997;255-257
16. Guy W., ECDEU Assessment Manual for Psychopharmacology. Revised, 1976. DHHS Publication No. (ADM) 91-338. Rockville, Md. US Dept of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration; National Institute of Mental Health, Psychopharmacology Research Branch, Division of Basic Brain and Behavioral Sciences.
17. Harati Y., Gooch C., Swenson M., Edelman S.V., Greene D., Rask Donofrio P., Cornblath D., Olson W.H., Kamin M. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabet Complications. 14:2000;65-70
18. Harvey A.T., Rudolph R.L., Preskorn S.H. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 57:2000;503-509
19. Horowitz S.H. Diabetic neuropathy. Clin Orthop. 1993;78-85
20. Huskisson E.C. Measurement of pain. Lancet. 2:1974;1127-1131
21. Jarvis B., Coukell A.J. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs. 56:1998;691-707
22. Jasmin L., Tien D., Janni G., Ohara P.T. Is noradrenaline a significant factor in the analgesic effect of antidepressants? Pain. 106:2003;3-8
23. Joss J.D. Tricyclic antidepressant use in diabetic neuropathy. Ann Pharmacother. 33:1999;996-1000
24. Kapur S., Mieczkowski T., Mann J.J. Antidepressant medications and the relative risk of suicide attempt and suicide. J Am Med Assoc. 268:1992;3441-3445
25. Lang E., Hord A.H., Denson D. Venlafaxine hydrochloride (Effexor™) relieves thermal hyperalgesia in rats with an experimental mononeuropathy. Pain. 68:1996;151-155
26. Marchand F., Alloui A., Chapuy E., Jourdan D., Pelissier T., Ardid D., Hernandez A., Eschalier A. Evidence for a monoamine mediated, opioid-independent, antihyperalgesic effect of venlafaxine, a non-tricyclic antidepressant, in a neurogenic pain model in rats. Pain. 103:2003;229-235
27. Max M.B. Antidepressants as analgesics. Fields H.L., Liebeskind J.C. Progress in Pain Research and Management. 1994;229-246 IASP Press, Seattle, WA
28. Max M.B., Kishore-Kumar R., Schafer S.C., Meister B., Gracely R.H., Smuller B., Dubner R. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain. 45:1991;3-9
29. Max M.B., Lynch S.A., Muir J., Shoaf S.E., Smoller B., Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 326:1992;1250-1256
30. McQuay H., Carroll D., Jadad A.R., Wiffen P., Moore A. Anticonvulsant drugs for management of pain: a systematic review. Br Med J. 311:1995;1047-1052
31. McQuay H.J., Tramèr M., Nye B.A., Carroll D., Wiffen P.J., Moore R.A. A systematic review of antidepressants in neuropathic pain. Pain. 68:1996;217-227
32. Mehtonen O.-P., Søgaard J., Roponen P., Behnke K., for the Venlafaxine 631 Study Group. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. J Clin Psychiatry. 61:2000;95-100
33. Mendels J., Johnston R., Mattes J., Riesenberg R. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull. 29:1993;169-174
34. Muth E.A., Haskins J.T., Moyer J.A., Husbands G.E.M., Nielsen S.T., Sigg E.B. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol. 35:1986;4493-4497
35. Ollat H., Cesaro P. Pharmacology of neuropathic pain. Clin Neuropharmacol. 18:1995;391-404
36. Partanen J., Niskanen L., Lehtinen J., Mervaala E., Siitonen O., Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 333:1995;89-94
37. Raskin A., Schulterbrandt J., Reatig N., Rice C.E. Factors of psychopathology in interview, ward behavior, and self-report ratings of hospitalized depressives. J Consult Psychol. 31:1967;270-278
38. Sacerdote P., Brini A., Mantegazza P., Panerai A.E. A role for serotonin and beta-endorphin in the analgesia induced by some tricyclic antidepressant drugs. Pharmacol Biochem Behav. 26:1987;153-158
39. Salerno S.M., Browning R., Jackson J.L. The effect of antidepressant treatment on lower back pain: a meta-analysis. Arch Intern Med. 162:2002;19-24
40. Schreiber S., Backer M.M., Pick C.G. The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neurosci Lett. 273:1999;85-88
41. Sindrup S.H., Jensen T.S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 83:1999;389-400
42. Sindrup S.H., Jensen T.S. Pharmacologic treatment of pain in polyneuropathy. Neurology. 55:2000;915-920
43. Sindrup S.H., Gram L.F., Brøsen K., Eshøj O., Mogensen E.F. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 42:1990;135-144
44. Sindrup S.H., Bjerre U., Dejgaard A., Brøsen K., Aaes-Jørgensen T., Gram L.F. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. 52:1992;547-552
45. Sindrup S.H., Bach F.W., Madsen C., Gram L.F., Jensen T.S. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology. 60:2003;1284-1289
46. Tasmuth T., Hartel B., Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain. 6:2002;17-24
47. Taylor K., Rowbotham M.C. Venlafaxine hydrochloride and chronic pain. West J Med. 165:1996;147-148
48. Thase M.E., for the Venlafaxine ER 209 Study Group. Efficacy and tolerability of once-daily venlafaxine extended release (ER) in outpatients with major depression. J Clin Psychiatry. 58:1997;393-398
49. Tylee A., Beaumont G., Bowden M.W., Reynolds A., on behalf of the General Practice Study Group. A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Primary Care Psychiatry. 3:1997;51-58
50. Watson C.P., Chipman M., Reed K., Evans R.J., Birkett N. Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial. Pain. 48:1992;29-36